Absci to Join Upcoming Investor Conferences
Absci Corporation (Nasdaq: ABSI), a pioneering company in data-driven generative AI for drug creation, has announced its participation in several upcoming investor conferences.
Details of the Conferences
Absci will take part in the following events:
Morgan Stanley Annual Global Healthcare Conference
A fireside chat is scheduled for Thursday, September 5 at 5:35 p.m. Eastern Time.
Citi Global TMT Conference
A fireside chat will take place on Friday, September 6 at 8:20 a.m. Eastern Time.
H.C. Wainwright Annual Global Investment Conference
A fireside chat is planned for Tuesday, September 10 at 12:00 p.m. Eastern Time.
About Absci
Absci is a company that focuses on generative AI for drug creation, combining AI with scalable wet lab technologies to accelerate the development of advanced biologics. Their Integrated Drug Creation™ platform aims to improve the efficiency of drug market entry by optimizing various critical drug characteristics at once. This cutting-edge method allows Absci to screen billions of cells each week, moving from AI-generated candidates to validated options in approximately six weeks. Absci operates out of Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center located in Zug, Switzerland.
Contact Information
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
Frequently Asked Questions
What is Absci Corporation?
Absci Corporation is a leader in generative AI-driven drug creation, utilizing advanced technologies to speed up the drug development process.
What types of conferences is Absci attending?
Absci is set to participate in several key investor conferences, including those organized by Morgan Stanley, Citi, and H.C. Wainwright.
When will the conferences take place?
The conferences are scheduled for early September, with specific dates for each fireside chat outlined in the announcement.
What advantages does Absci's technology offer for drug development?
Absci’s technology enhances the optimization of drug characteristics simultaneously, which increases the likelihood of success and shortens the time needed to bring therapies to market.
How can investors get in touch with Absci?
Investors can contact Absci's VP of Finance & Investor Relations, Alex Khan, using the email address provided in the contact section.